Phenotypic and functional dysregulated blood NK cells in colorectal cancer patients can be activated by cetuximab plus IL-2 or IL-15

Frontiers in Immunology

Volumn 7, Issue OCT, 2016, Pages

  Rocca, Yamila Sol ^a   Roberti, María Paula ^b   Juliá, Estefanía Paula ^b   Pampena, María Betina ^b   Bruno, Luisina ^c   Rivero, Sergio ^c   Huertas, Eduardo ^c   Loria, Fernando Sánchez ^c   Pairola, Alejandro ^c   Caignard, Anne ^d,e   Mordoh, José ^a,b,c   Levy, Estrella Mariel ^b  

^a FUNDACIÓN INSTITUTO LELOIR   (Argentina)

^b Instituto Médico Especializado Alexander Fleming   (Argentina)

^c INSTITUTO ALEXANDER FLEMING   (Argentina)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Cetuximab; Colorectal cancer; IL 15; IL 2; Natural killer cells; NKp30; NKp46

Indexed keywords

CETUXIMAB; INTERLEUKIN 15; INTERLEUKIN 2; LENALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NATURAL KILLER CELL; PROTEIN EXPRESSION; TUMOR LOCALIZATION; TUMOR MICROENVIRONMENT;

EID: 84997282718     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00413     Document Type: Article

References (58)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin (2013) 63:11-30. doi:10.3322/caac.21166.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst (2004) 96:1420-5. doi:10.1093/jnci/djh275.
3. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 350:2335-42. doi:10.1056/NEJMoa032691.
4. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 355(24):2542-50.
5. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer (2012) 11:1-13. doi:10.1016/j.clcc.2011.05.005.
6. Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall'Olio FG, et al. Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis. World J Gastroenterol (2016) 22(2):519-33. doi:10.3748/wjg.v22.i2.519.
7. Eggermont A, Robert C, Soria JC, Zitvogel L. Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. Oncoimmunology (2014) 3(1):e27560. doi:10.4161/onci.27560.
8. Pagès F, Galon J, Dieu-Nosjean MC, Tartour E, Sautès-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2010) 29:1093-102. doi:10.1038/onc.2009.416.
9. Osada T, Hsu D, Hammond S, Hobeika A, Devi G, Clay TM, et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody. Br J Cancer (2009) 102:124-33. doi:10.1038/sj.bjc.6605364.
10. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. Innate or adaptive immunity? The example of natural killer cells. Science (2011) 331(6013):44-9. doi:10.1126/science.1198687.
11. Vivier E, Ugolini S. Natural killer cells: from basic research to treatments. Front Immunol (2011) 2:18. doi:10.3389/fimmu.2011.00018.
12. Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol (2012) 12:239-52. doi:10.1038/nri3174.
13. Romagne F, Vivier E. Natural killer cell-based therapies. F1000 Med Rep (2011) 3:9. doi:10.3410/M3-9.
14. Ljunggren HG, Malmberg KJ. Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol (2007) 7:329-39. doi:10.1038/nri2073.
15. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science (2004) 306:1517-9. doi:10.1126/science.1103478.
16. Narni-Mancinelli E, Ugolini S, Vivier E. Tuning the threshold of natural killer cell responses. Curr Opin Immunol (2013) 25:53-8. doi:10.1016/j.coi.2012.11.005.
17. Krzewski K, Strominger JL. The killer's kiss: the many functions of NK cell immunological synapses. Curr Opin Cell Biol (2008) 20:597-605. doi:10.1016/j.ceb.2008.05.006.
18. Moretta A, Marcenaro E, Sivori S, Della Chiesa M, Vitale M, Moretta L. Early liaisons between cells of the innate immune system in inflamed peripheral tissues. Trends Immunol (2005) 26:668-75. doi:10.1016/j.it.2005.09.008.
19. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A, et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol (2004) 5:1260-5. doi:10.1038/ni1138.
20. Vitale M, Cantoni C, Pietra G, Mingari MC, Moretta L. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol (2014) 44(6):1582-92. doi:10.1002/eji.201344272.
21. Rocca YS, Roberti MP, Arriaga JM, Amat M, Bruno L, Pampena MB, et al. Altered phenotype in peripheral blood and tumor-associated NK cells from colorectal cancer patients. Innate Immun (2013) 19(1):76-85. doi:10.1177/1753425912453187.
22. Peng YP, Zhu Y, Zhang JJ, Xu ZK, Qian ZY, Dai CC, et al. Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer. J Transl Med (2013) 11:262. doi:10.1186/1479-5876-11-262.
23. Hou H, Mao L, Wang J, Liu W, Lu Y, Yu J, et al. Establishing the reference intervals of NK cell functions in healthy adults. Hum Immunol (2016) 77(8):637-42. doi:10.1016/j.humimm.2016.05.022.
24. Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, et al. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial. J Clin Oncol (2013) 31(19):2477-84. doi:10.1200/JCO.2012.46.0543.
25. Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, et al. Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. Clin Cancer Res (2016) 22(10):2435-44. doi:10.1158/1078-0432.CCR-15-0414.
26. Zhu J, Wang X, Xu X, Abassi YA. Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods (2006) 309:25-33. doi:10.1016/j.jim.2005.10.018.
27. The KIR Gene Cluster. Mary Carrington and Paul Norman. Bethesda, MD: National Center for Biotechnology Information (US) (2003).
28. Fregni G, Messaoudene M, Fourmentraux-Neves E, Mazouz-Dorval S, Chanal J, Maubec E, et al. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages. PLoS One (2013) 8(10):e76928. doi:10.1371/journal.pone.0076928.
29. Perier A, Fregni G, Wittnebel S, Gad S, Allard M, Gervois N, et al. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma. Oncogene (2011) 30(23):2622-32. doi:10.1038/onc.2010.638.
30. LeMaoult J, Zafaranloo K, Le DanffC, Carosella ED. HLA-G upregulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J (2005) 19:662-4. doi:10.1096/fj.04-1617fje.
31. Jewett A, Tseng HC. Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells. J Cancer (2011) 2:443-57. doi:10.7150/jca.2.443.
32. Bellone G, Aste-Amezaga M, Trinchieri G, Rodeck U. Regulation of NK cell functions by TGF-beta 1. J Immunol (1995) 155(3):1066-73.
33. Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 17(9):1025-36. doi:10.1038/ni.3518.
34. Halama N, Braun M, Kahlert C, Spille A, Quack C, Rahbari N, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin Cancer Res (2011) 17(4):678-89. doi:10.1158/1078-0432.CCR-10-2173.
35. Malladi S, Macalinao DG, Jin X, He L, Basnet H, Zou Y, et al. Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell (2016) 165(1):45-60. doi:10.1016/j.cell.2016.02.025.
36. Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, et al. Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade. Eur J Immunol (2015) 45(5):1560-9. doi:10.1002/eji.201445353.
37. Mamessier E, Pradel LC, Thibult ML, Drevet C, Zouine A, Jacquemier J, et al. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol (2013) 190:2424-36. doi:10.4049/jimmunol.1200140.
38. Le Maux Chansac B, Moretta A, Vergnon I, Opolon P, Lécluse Y, Grunenwald D, et al. NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors. J Immunol (2005) 175:5790-8. doi:10.4049/jimmunol.175.9.5790.
39. Garcia-Iglesias T, Del Toro-Arreola A, Albarran-Somoza B, Del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Dueñas MG, et al. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer (2009) 9:186. doi:10.1186/1471-2407-9-186.
40. Watanabe M, Kono K, Kawaguchi Y, Mizukami Y, Mimura K, Maruyama T, et al. NK cell dysfunction with down-regulated CD16 and up-regulated CD56 molecules in patients with esophageal squamous cell carcinoma. Dis Esophagus (2010) 23:675-81. doi:10.1111/j.1442-2050.2010.01073.x.
41. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self-tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest (2011) 121:3609-22. doi:10.1172/JCI45816.
42. Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 71:5412-22. doi:10.1158/0008-5472.CAN-10-4179.
43. Schleypen JS, Baur N, Kammerer R, Nelson PJ, Rohrmann K, Grone EF, et al. Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin Cancer Res (2006) 12:718-25. doi:10.1158/1078-0432.CCR-05-0857.
44. Delahaye NF, Rusakiewicz S, Martins I, Ménard C, Roux S, Lyonnet L, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 17:700-7. doi:10.1038/nm.2366.
45. Pasero C, Gravis G, Guerin M, Granjeaud S, Thomassin-Piana J, Rocchi P, et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res (2016) 76(8):2153-65. doi:10.1158/0008-5472.CAN-15-1965.
46. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol (2001) 19:197-223. doi:10.1146/annurev.immunol.19.1.197.
47. Srour EF, Leemhuis T, Jenski L, Redmond R, Jansen J. Cytolytic activity of human natural killer cells subpopulations by four colour immunofluorescence flow cytometric sorting. Cytometry (1990) 11:442-6. doi:10.1002/cyto.990110316.
48. Fuchshuber PR, Lotzova E. Differential oncolytic effect of NK-enriched subsets in long-term interleukin-2 cultures. Lymphokine Cytokine Res (1992) 11:271-6.
49. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, et al. The tryptophan catabolite L kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK cell function. Blood (2006) 108(13):4118-25. doi:10.1182/blood-2006-03-006700.
50. Park YP, Choi SC, Kiesler P, Gil-Krzewska A, Borrego F, Weck J, et al. Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. Blood (2011) 118(11):3019-27. doi:10.1182/blood-2011-04-346825.
51. Orleans-Lindsay JK, Barber LD, Prentice HG, Lowdell MW. Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function-implications for the adoptive immunotherapy of leukaemia. Clin Exp Immunol (2001) 126(3):403-11. doi:10.1046/j.1365-2249.2001.01692.x.
52. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci U S A (2003) 100(7):4120-5. doi:10.1073/pnas.0730640100.
53. Friese MA, Wischhusen J, Wick W, Weiler M, Eisele G, Steinle A, et al. RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo. Cancer Res (2004) 64(20):7596-603. doi:10.1158/0008-5472.CAN-04-1627.
54. Ikushima H, Miyazono K. TGF beta signalling: a complex web in cancer progression. Nat Rev Cancer (2010) 10:415-24. doi:10.1038/nrc2853.
55. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol (2004) 172:7335-40. doi:10.4049/jimmunol.172.12.7335.
56. Seeger P, Musso T, Sozzani S. The TGF-β superfamily in dendritic cell biology. Cytokine Growth Factor Rev (2015) 26(6):647-57. doi:10.1016/j.cytogfr.2015.06.002.
57. Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol (2014) 164(6):811-21. doi:10.1111/bjh.12708.
58. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med (2007) 357:2040-8. doi:10.1056/NEJMoa071834.